Stephen Fesik

Pending COVID-19 samples are prepared for testing in the Diagnostic Laboratories at VUMC.
November 3, 2022

Event to spotlight VUMC’s COVID-19 research efforts

The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.

By Bill Snyder
March 28, 2019

Cancer’s SOS

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.

By Sanjay Mishra
close up of mans arm as he receives chemotherapy infusion
March 14, 2018

Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer

New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.

By Bill Snyder
microscope
June 23, 2016

VU takes key role in cancer drug discovery consortium

Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery.

By Leigh MacMillan
May 19, 2016

VICC investigators in spotlight at AACR conference

A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures.

By VUMC News and Communications
March 26, 2015

‘Docking stations’ on chromosomes new anti-cancer target

Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks.

By Bill Snyder